Alternative Approaches for Acute Inhalation Toxicity Testing | PSCI Webinar

Added:

The Continued Necessity of In Vivo Animal Models in Regulatory Inhalation Toxicology

While human-based in vitro and in silico models represent significant technological advancements, a prominent counterpoint in regulatory toxicology emphasizes the continued necessity of in vivo animal testing. Proponents of this view argue that current alternative models cannot fully replicate the complex, systemic physiological responses of a whole organism. Acute inhalation toxicity involves intricate, multi-organ interactions, including systemic circulation, immune system activation, neural reflexes, and complex clearance mechanisms that in vitro systems (like lung-on-a-chip or 3D tissue models) fail to capture adequately. Regulatory agencies often require in vivo data to ensure human safety, as relying solely on simplified alternatives could lead to underestimating systemic risks or missing unexpected toxicological endpoints. Consequently, animal models remain the gold standard for comprehensive hazard identification and risk assessment in inhalation toxicology.

Fundamentals of toxicology, specifically the distinction between acute, sub-chronic, and chronic toxicity testing.
Basic anatomy and physiology of the human respiratory system, including the structure and function of the upper and lower airways.
Traditional in vivo inhalation testing methods (such as LC50 tests in rodents) and their role in regulatory safety assessment.
The ethical framework of the '3Rs' (Replacement, Reduction, and Refinement) in animal research.
Advanced in vitro and ex vivo lung models, such as 3D reconstituted human airway epithelial models and lung-on-a-chip technologies.
The regulatory validation process (e.g., OECD test guidelines) required for New Approach Methodologies (NAMs) to officially replace animal tests.
Adverse Outcome Pathways (AOPs) relevant to respiratory toxicity, linking molecular initiating events to organ-level outcomes.
Computational (in silico) deposition modeling of aerosols and particles within the human respiratory tract to predict localized dosage.
1.3K views7likes49:47@thePSCIOriginal Release: 2016-09-08

Human lung tissue models, including the Normal Human Bronchial Epithelial (NHBE) model and microengineered lung-on-a-chip devices, provide physiologically relevant alternatives to animal testing for inhalation toxicity assessment. The NHBE model uses primary human bronchial epithelial cells that differentiate into seven cell types (ciliated, goblet, Clara, intermediate, and basal cells) forming a stratified structure with tight junctions, enabling real-time monitoring of barrier integrity through electrical resistance measurements and detection of inflammatory responses via cytokine profiling. The lung-on-a-chip technology further advances this field by creating microfluidic devices that mimic the alveolar-capillary interface with cyclic breathing motions, allowing researchers to model complex physiological processes such as immune cell recruitment during infection and drug-induced pulmonary edema. These human tissue-based models offer improved predictability for respiratory toxicity compared to traditional animal models, with validation studies showing 77% correlation with in vivo results, and represent a promising approach for reducing reliance on animal testing while advancing understanding of respiratory disease mechanisms and developing safer therapeutic interventions.